// App-Quantinova.ai

P313 : Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

Researchers

Presenter

  • E V Loftus Jr

Principal Investigators

  • D T Rubin

  • J Panes

  • D Pugatch

  • W Zhou

  • S Goteti

  • A Lacerda

  • S Travis

Medical Centers

  • Mayo Clinic, Rochester, Minnesota

  • University of Chicago Medicine, Chicago, Illinois, USA

  • Hospital Clinic Barcelona, Barcelona, Spain

  • AbbVie Inc., North Chicago, Illinois, United States

  • Oxford University Hospital, Oxford,

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Plasminogen Activator, Urokinase

  • Human albumin

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02365649

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved